NASDAQ: EMBCEmbecta Corp Stock
$10.17+0.17 (+1.7%)
Updated Feb 13, 2026
EMBC Price
$10.17
Fair Value Price
$27.72
Market Cap
$602.27M
52 Week Low
$9.20
52 Week High
$15.72
P/E
4.26x
P/B
-0.98x
P/S
0.64x
PEG
0.51x
Dividend Yield
5.9%
Revenue
$1.08B
Earnings
$139.50M
Gross Margin
63.1%
Operating Margin
27.73%
Profit Margin
12.9%
Debt to Equity
-2.74
Operating Cash Flow
$214M
Beta
0.94
Next Earnings
N/A
Ex-Dividend
Feb 27, 2026
Next Dividend
Mar 17, 2026
EMBC Overview
Embecta Corp. is a medical device company offering various solutions to people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist with the management of diabetes. The company sells its products to wholesalers and distributors in the U.S and internationally. Embecta was founded in 1924 and is based in Parsippany, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EMBC's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
EMBC
Ranked#4 of 44
Ranked#4 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $28.97 | A | |
| $7.54 | A | |
| $4.67 | A |
Be the first to know about important EMBC news, forecast changes, insider trades & much more!
EMBC News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EMBC scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EMBC ($10.17) is undervalued by 63.31% relative to our estimate of its Fair Value price of $27.72 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EMBC ($10.17) is significantly undervalued by 63.31% relative to our estimate of its Fair Value price of $27.72 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
EMBC ($10.17) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more EMBC due diligence checks available for Premium users.
Valuation
EMBC fair value
Fair Value of EMBC stock based on Discounted Cash Flow (DCF)
Price
$10.17
Fair Value
$27.72
Undervalued by
63.31%
EMBC ($10.17) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EMBC ($10.17) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EMBC ($10.17) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EMBC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
4.26x
Industry
175.02x
Market
43.96x
EMBC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
EMBC is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
EMBC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.98x
Industry
3.04x
EMBC price to earnings growth (PEG)
For valuing profitable companies with growth potential
EMBC is good value based... subscribe to Premium to read more.
PEG Value Valuation
EMBC's financial health
Profit margin
Revenue
$261.2M
Net Income
$44.1M
Profit Margin
16.9%
EMBC's Earnings (EBIT) of $299.40M... subscribe to Premium to read more.
Interest Coverage Financials
EMBC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.1B
Liabilities
$1.7B
Debt to equity
-2.74
EMBC's short-term assets ($620.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EMBC's long-term liabilities ($1.44B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EMBC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EMBC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$17.2M
Investing
$9.5M
Financing
-$51.6M
EMBC's operating cash flow ($214.20M)... subscribe to Premium to read more.
Debt Coverage Financials
EMBC vs Medical Stocks
Embecta Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.